FDA approves Zepbound, a new obesity drug that will take on Wegovy

Eli Lilly said the obesity medicine, which helped adults in clinical studies lose about 20% of their body weight, will be available in the U.S. by the end of the year. The list price will be $1,060.

Related Keywords

United States ,Americans ,John Sharretts ,Mike Mason ,Joe Nadglowski ,Eli Lilly Co ,Novo Nordisk ,Division Of Diabetes ,Drug Administration ,Obesity Action Coalition ,Drug Administration Wednesday ,Lipid Disorders ,Drug Evaluation ,